By Daniela Schardinger published on Forbes.com After regulatory approval, medtech startups enter a uniquely exposed phase. The product is cleared, years of development are behind them and expectations rise quickly. Boards want validation. Investors want proof of market response. Regulators expect post-market vigilance. Revenue becomes the most visible signal of success. Often, it feels like the only one. This is why many startups move quickly from approval to launch. Not nece

Forbes Expert Panel Contribution — Daniela Schardinger. From economic uncertainty to rapid technological change, an unpredictable economic environment is presenting an ongoing challenge for industry leaders. While time-tested strategies still have value, embracing unconventional tactics can not only unlock new opportunities but also take a business to the next level. In a marketplace that rewards adaptability, experimentation and fresh thinking, staying ahead requires more th

Forbes Expert Panel Contribution — Daniela Schardinger When a business depends on its sales team to find leads and close deals, the way company leaders approach onboarding for new sales hires makes all the difference. From clearly outlined onboarding processes and knowledge banks to easily accessible mentors, effectively onboarding new hires means offering both initial and ongoing support. The members of Forbes Business Council have ample experience developing onboarding pro

By Daniela Schardinger published on Forbes.com Every year, thousands of biotech breakthroughs stall. Not because the science failed, but because the story did. A survey of biotech investors found that 86% believe that fewer than half of management teams communicate effectively , directly hurting their ability to secure funding and partnerships. In other words, brilliant science is not enough. If you cannot articulate its value clearly and compellingly, discoveries may never s